Market News & Trends
AMRI Expands Sterile Production Capacity
AMRI, a global contract research, development and manufacturing organization, is expanding its sterile manufacturing capacity. The addition of an aseptic pre-filled syringe filling line at…
GSK Exercises Option Over Adaptimmune’s SPEAR T-Cell Therapy Program
Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, recently announced that GlaxoSmithKline plc has exercised its option under a collaboration and license…
Novartis AG Receives First Ever FDA Approval for CAR-T
A new era in cancer treatment is now here. The US FDA recently gave the nod to Switzerland-based Novartis AG for its gene therapy cancer…
Immunovaccine Announces Achievement of Milestones in Collaboration with Zoetis
Immunovaccine Inc., a clinical-stage immuno-oncology company, recently announced the achievement of several milestones in its ongoing collaboration with global animal health company Zoetis to develop…
Genmab & Seattle Genetics to Co-Develop Tisotumab Vedotin for Solid Tumors
Genmab A/S and Seattle Genetics, Inc. recently announced that Seattle Genetics, Inc. has exercised its option to co-develop tisotumab vedotin. The companies originally entered into…
Asia-Pacific Hepatitis C Market to Surpass $8.3 Billion by 2023
The hepatitis C market across the Asia-Pacific (APAC) region, which includes India, China, Australia, South Korea and Japan, is forecast to grow from $5.3 billion…
Rexahn Pharmaceuticals Receives New US Patent
Rexahn Pharmaceuticals, Inc. recently announced that the United States Patent and Trademark Office has issued US Patent No. 9,744,167, Nanoparticulate Formulations and Compositions of Piperazine…
Abeona Therapeutics Receives FDA Breakthrough Therapy Designation
Abeona Therapeutics Inc. recently announced the US FDA has granted Breakthrough Therapy designation status to the company’s EB-101 gene therapy program for patients with Recessive…
Sanofi Completes the Acquisition of Protein Sciences
Sanofi recently announced it has completed the acquisition of Protein Sciences, a vaccines biotechnology company based in Meriden, CT. This completion follows Federal Trade Commission…
Huber Closes $630-Million Sale of Silica Business to Evonik
The J.M. Huber Corporation has completed the sale of the Silica business unit of Huber Engineered Materials (HEM) to Evonik Industries AG, a global specialty…
Roquette Completes Acquisition, Reinforces Ambition of Being Excipient Leader
Roquette, a global leader in innovative plant-based ingredients, recently announced it has completed the acquisition of Itacel from Blanver. Itacel is a leading player…
Dr. Christian Fischer to Succeed Uwe Röhrhoff as CEO of Gerresheimer AG
With effect from September 1, 2017, Dr. Christian Fischer (53) is to assume responsibility as Chief Executive Officer of Gerresheimer AG. He succeeds Uwe Röhrhoff…
Jupiter Orphan Therapeutics Receives Orphan Drug Designation
Jupiter Orphan Therapeutics, Inc. recently announced it has received notification from the US Food and Drug Administration (FDA) that its Orphan Drug Designation request for…
PharmAkea Announces Successful Completion of a Phase 1 Trial
PharmAkea, Inc. recently announced it has successfully completed a Phase 1 single and multiple ascending dose (SAD/MAD) clinical study with PAT-1251, its novel, small-molecule LOXL2…
REGENXBIO to Acquire Dimension Therapeutics
REGENXBIO Inc. and Dimension Therapeutics, Inc. recently announced they have entered into a definitive agreement under which REGENXBIO will acquire Dimension in an all-stock transaction…
Intra-Cellular Therapies Announces Positive Regulatory Update
Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, recently announced that the U.S. Food and…
SiO2 Medical Products & Sanaria Sign Agreement for Cryogenic Vials
SiO Medical Products, Inc., a U.S.-based designer, developer, manufacturer, and supplier of pharmaceutical packaging, labware, and consumables products, and Sanaria Inc., a U.S.-based developer, manufacturer,…
Novartis Injection Could Prevent Heart Attacks, Slash Cancer Risk
By Ben Spencer, Medical Correspondent Thousands of lives could be saved thanks to a new heart drug hailed as the biggest breakthrough since…
Enteris Biopharma Doses First Woman in Phase 2a Clinical Trial
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, recently announced the first woman has been dosed in…
Ajinomoto Althea, Inc. Announces New Aseptic Fill Finish Line
Ajinomoto Althea, a leading service provider of biopharmaceutical contract development and manufacturing drug programs, announces the installation and launch of a new high-performance sterile…
